Liver cancer
Conditions
Interventions
Control group:Anlotinib
Experimental group:TACE combined with Anlotinib
Sponsors
The People’s Hospital of HeChi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 18-80 years old patients with hepatocellular carcinoma, pre-survival period of more than 12 weeks; 2. Liver cancer lesions meet BCLC-B/C phase; 3. Liver function Child-Pugh score = 7 points; 4. ECOG score = 1 point; 5. 0-2 TACE treatment before surgery; 6. The patient and/or family agree to join the clinical trial and sign an informed consent form: 7. There are follow-up conditions:
Exclusion criteria
Exclusion criteria: 1. The portal vein is completely embolized, and the collateral vessels are less formed; 2. Extrahepatic spread, including patients with inferior vena cava invasion; 3. Patients who are ready for liver transplantation; 4. Abnormal blood coagulation (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds), with bleeding tendency or receiving thrombolytic or anticoagulant therapy; 5. Received molecular targeted drug therapy, radiotherapy, chemotherapy, etc., other than erlotinib before enrollment; 6. Severe dysfunction of organs such as heart, lung, kidney and brain; 7. Peripheral blood leukocytes caused by chemotherapy drugs or other drugs 160 mmHg, diastolic blood pressure >100 mmHg); 14. Urine routinely shows urinary protein = ++ or confirmed 24-hour urine protein quantitation > 1.0g; 15. Pregnant or lactating women; 16. Have a history of mental illness or psychotropic substance abuse; 17. Patients and/or family members do not agree to join a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;progression free survival,; | — |
Countries
China
Contacts
Public ContactWei Song
The People’s Hospital of HeChi
Outcome results
None listed